Hexamethonium

From Wikipedia, the free encyclopedia
Jump to: navigation, search
Hexamethonium
Hexamethonium.png
Systematic (IUPAC) name
N,N,N,N',N',N'-hexamethylhexane-1,6-diaminium
Clinical data
Pregnancy cat. D
Legal status Prescription only
Identifiers
CAS number 60-26-4 N
ATC code ?
PubChem CID 3604
ChemSpider 3478 YesY
UNII 3C9PSP36Z2 YesY
ChEMBL CHEMBL105608 N
Chemical data
Formula C12H30N2 
Mol. mass 202.38 g/mol
 N (what is this?)  (verify)

Hexamethonium is a non-depolarising ganglionic blocker, a nicotinic nACh (NN) receptor antagonist[1] that acts in autonomic ganglia by binding mostly in or on the NN receptor, and not the acetylcholine binding site itself. It does not have any effect on the muscarinic acetylcholine receptors (mAChR) located on target organs of the parasympathetic nervous system but acts as antagonist at the nicotinic acetylcholine receptors located in sympathetic and parasympathetic ganglia (NN).[2]

Pharmacology[edit]

It can act on receptors at pre-ganglionic sites in both the sympathetic and parasympathetic nervous systems, which are both regulated by nicotinic ligand-gated ionotropic acetylcholine receptors. Postganglionic sympathetic systems are usually regulated by norepinephrine (noradrenaline) (adrenergic receptors), whereas parasympathetic systems are acetylcholine-based, and instead rely on muscarinic receptors (some post-ganglionic sympathetic neurons, such as those stimulating sweat glands, release acetylcholine).

The organ system and adverse effects of ganglion blockers are due to the parasympathetic and sympathetic stimuli blockage at preganglionic sites. Side-effects include combined sympatholytic (e.g., orthostatic hypotension and sexual dysfunction) and parasympatholytic (e.g., constipation, urinary retention, glaucoma, blurry vision, decreased lacrimal gland secretion, dry mouth (xerostomia)) effects.

Uses[edit]

It was formerly used to treat disorders, such as chronic hypertension, of the peripheral nervous system, which is innervated only by the sympathetic nervous system. The non-specificity of this treatment led to discontinuing its use.[3]

The use of inhaled hexamethonium, an unapproved drug, in a normal volunteer during a medical study is believed to have caused or contributed to her death[4][5] in light of the presence of abnormal "ground glass opacities" on her chest X-ray.

See also[edit]

References[edit]

  1. ^ "Hexamethonium - Compound Summary". http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=3604. 2013-06-18. 
  2. ^ Howland RD, Mycek MJ 2006. Lippincott's illustrated reviews: Pharmacology. 3:d edition, page 47.
  3. ^ Hardman et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 10th edition, 2001, pp 210-211.
  4. ^ "Johns Hopkins’ Tragedy: Could Librarians Have Prevented a Death?". Retrieved 2008-10-06. 
  5. ^ Savulescu J, Spriggs M (February 2002). "The hexamethonium asthma study and the death of a normal volunteer in research". Journal of Medical Ethics 28 (1): 3–4. doi:10.1136/jme.28.1.3. PMC 1733509. PMID 11834748.